Abstract:<p>The complement system was discovered at the end of the 19th century as a heat-labile plasma component that "complemented" the antibodies in killing microbes, hence the name "complement." Complement is also part of the innate immune system, protecting the host by recognition of pathogen-associated molecular patterns. However, complement is multifunctional far beyond infectious defense. It contributes to organ development, such as sculpting neuron synapses, promoting tissue regeneration and repair, and rapidly engaging and synergizing with a number of processes, including hemostasis leading to thromboinflammation. Complement is a double-edged sword. Although it usually protects the host, it may cause tissue damage when dysregulated or overactivated, such as in the systemic inflammatory reaction seen in trauma and sepsis and severe coronavirus disease 2019 (COVID-19). Damage-associated molecular patterns generated during ischemia-reperfusion injuries (myocardial infarction, stroke, and transplant dysfunction) and in chronic neurologic and rheumatic disease activate complement, thereby increasing damaging inflammation. Despite the long list of diseases with potential for ameliorating complement modulation, only a few rare diseases are approved for clinical treatment targeting complement. Those currently being efficiently treated include paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, myasthenia gravis, and neuromyelitis optica spectrum disorders. Rare diseases, unfortunately, preclude robust clinical trials. The increasing evidence for complement as a pathogenetic driver in many more common diseases suggests an opportunity for future complement therapy, which, however, requires robust clinical trials; one ongoing example is COVID-19 disease. The current review aims to discuss complement in disease pathogenesis and discuss future pharmacological strategies to treat these diseases with complement-targeted therapies.</p>Significance Statement<p>The complement system is the host's defense friend by protecting it from invading pathogens, promoting tissue repair, and maintaining homeostasis. Complement is a double-edged sword, since when dysregulated or overactivated it becomes the host's enemy, leading to tissue damage, organ failure, and, in worst case, death. A number of acute and chronic diseases are candidates for pharmacological treatment to avoid complement-dependent damage, ranging from the well established treatment for rare diseases to possible future treatment of large patient groups like the pandemic coronavirus disease 2019.</p>

The potential application of complement inhibitors-loaded nanosystem for autoimmune diseases via regulation immune balance

Bioinspired membrane-based nanomodulators for immunotherapy of autoimmune and infectious diseases

Nanoparticle-neutrophils interactions for autoimmune regulation

Low-dimensional nanomaterials enabled autoimmune disease treatments: Recent advances, strategies, and future challenges

Biocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases

An Autoimmune Epitope on C-reactive Protein Targets Complement Regulation in Lupus Nephritis

Complement-targeted therapy for autoimmune diseases

Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts

The complement system and autoimmune diseases

New understanding of complement in childhood immune and/or inflammatory renal diseases

Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins

Therapeutic Intervention of Neuroinflammatory Alzheimer Disease Model by Inhibition of Classical Complement Pathway with the Use of Anti-C1r Loaded Exosomes

Complement in neurological disorders and emerging complement-targeted therapeutics

Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics

Clinical promise of next-generation complement therapeutics

Nanocarriers for effective delivery: modulation of innate immunity for the management of infections and the associated complications

The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases?

Urinary complement biomarkers in immune-mediated kidney diseases

New topic of complement and diseases

Therapeutically targeting the classical complement pathway with antisense oligonucleotides in Alzheimer′s disease

The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy